MedTrace Logo

Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device

NCT06807502 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2026-04-24

No results posted yet for this study

Summary

Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.

The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up

Conditions

  • Breast Cancer, Metastatic
  • Breast Cancer Invasive
  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions

DEVICE

The DM/DIV ScreenCell is the experimental product studied during this research

The product is not used directly on the subject, but on a blood sample taken from the participant.

Sponsors & Collaborators

  • AXELYS SANTE

    collaborator UNKNOWN

  • ScreenCell

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2026-09-30
Completion
2026-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06807502 on ClinicalTrials.gov